Imiphumo emibi yeTarceva kunye nento ongayenza ukulwa nayo
I-Tarceva (erlotinib) ngumhlaza ojoliswe kumhlaza okhethwe ukuba uphathise umhlaza wesifo somhlaza wesifo esingekho encinci kunye nomdlavuza wepancreatic (kunye ne-gemcitabine chemotherapy). Isebenza ngokujolisa kwiprotheyini ebizwa ngokuba yi-epidermal growth factor receptor (EGFR) eyenza ukukhushulwa kwe-cell cell growth. Yilonyango lomlomo kwaye lichazwe kwifom yefribhethi.
I-Tarceva Side Effects
Njengoko nayiphi na imichiza yomhlaza, kunokuba nemiphumo emibi. Qiniseka ukuba uxoxe ngazo naziphi na iimpawu zale ngogqirha ukuba zivela. Iimpembelelo eziqhelekileyo zeTarceva ziquka:
Rash kunye neTarceva
Iisalathisi ezinxulumene neTarceva zivame ukuvela kwiintsuku ezili-10 zokuqala unyango. Abo bathatha i-Tarceva ngokudibanisa ne-gemcitabine bangavelisa ukukhawuleza nayiphi na ixesha ngexesha lonyango. I-Tarceva ihlamba ibonakala njenge-acne okanye isikhumba esomileyo kwaye ingavela emzimbeni nasebusweni. Ngokuqhelekileyo ibonakala ivela enqeni. Kweminye, ukukhawuleza kunokuba yinto enqabileyo okanye uzive ngathi ukutshisa ilanga. Akunabo bonke abantu abaza kuhlakulela ukukhwabanisa kwesikhumba eTarceva. Abo bahlakulela ukukhawuleza baxela ukuxhaswa ngexesha lotyando kwaye njengoko umlinganiselo wehlisa.
Uphononongo luka-2007 lufumene ukuba abo baqalisa ukukhawuleza ngelixa bethatha iTarceva babeneziphumo ezingcono kunezo ezingazange zenze. Akunjalo ukuba isilwanyana asizange siphumelele nakwabo kulabo abangazange bahlasele, kodwa abo bahlakulele ukukhawuleza babenokuzuza.
Ngoko ke, ngelixa ukugqithisa okuhambelana nokusetyenziswa kweTarceva kubonakala kukuhle ngabantu abane-oncologists, akusisiqinisekiso.
Kubaluleke kakhulu ukuba uvumele ugqirha wakho ukuba wazi ukuba uqala ukuhlakulela ukukhawuleza. Musa ukusebenzisa nayiphi na imishanguzo yokuphatha ukukhawuleza, thintela nakwi-counter okanye imithi yamachiza. Qhagamshelana nodokotela wakho kuqala.
Ugqirha wakho unokumisela i-antibiotics okanye i-martiyiti enye ukuze uncede ngokukhawuleza. Abanye banokuzuza kwixesha lokuyeka unyango, nokuba ngaba nje iintsuku ezimbalwa.
Kubalulekile ukuba uqaphele ukuba ukukhwabanisa okukhulu kwesikhumba kwenzeka ngethuba leemvavanyo zeclini. Ingumphumo wecala ongaqhelekanga othe wafaniswa ne-Stevens-Johnsons syndrome, imeko enokuthi ibhubhise ebangelwa ukusabela okubi kakhulu kwiyeza.
Uhudo kunye neTarceva
Olunye umphumo wesiganeko oqhelekileyo lweTarceva luhudo. Ukuxhalabisa ngesifo sohudo kukuba kungakhokelela ekudambiseni amanzi, ngoko ufuna ukuxoxisana nale ngxaki nodokotela wakho. Nangona ikwazi ukulawulwa rhoqo kunye neyeza zokulwa ne-diarrhea , qhagamshelana nogqirha wakho ngaphambi kokuba uthathe nantoni na. Unako ukufumana iingcebiso ezithile malunga ne-brand kunye nomyinge. Ukuba isifo sohudo siphepha okanye asikwazi ukulawulwa ngamachiza angaphezu kwe-counter, nceda ugqirha ugqirha wakho.
Ezinye iziphumo eziqhelekileyo zeTarceva
Ezinye iziphumo eziqhelekileyo zeTarceva zibandakanya ukulahlekelwa kwesidlo, ukukhathala, isisongela kunye nokuhlanza. Njalo khumbula ukuxelela ugqirha wakho nayiphina imiphumo oyingozi.
I-Tarceva Side Side Effects
Kwizilingo zeklinikhi, ezi ziqhamo ezingabonakaliyo zecala laseTarceva zaphawula:
- emathunjini emathumbu
- isifo seemiphunga
- Umonakalo weentso / isibindi
- umonakalo emehlweni
Qinisekisa ukubonelela ugqirha wakho unembali yezempilo enempilo ebandakanya yonke imishanguzo yamachiza, imithi yamachiza, kunye nezidakamizwa zemithi oyithathayo. Ezinye iimeko zingakwandisa umngcipheko wokuphuhlisa iziphumo ezingekho phantsi kwesiqhelo.
Gcina ukhumbule ukuba ezi ziyimiphumo emibi kakhulu. Ukuba ukhathazekile ngemingcipheko yale miphumo emibi, xela ugqirha wakho. Nonke, unokuxoxa ngezibonelelo ngokubhekiselele kwiingozi zokuthatha iTarceva.
Xa Ubiza iDokotela wakho
Biza ugqirha wakho ukuba:
- phuhlisa umkhuhlane
- ukufumana ukuphefumula kokuphefumula
- ukuva isohlo
- Ukuphuhliswa kwesikhumba okanye ukugqithisa kwakho kunzima
- unomkhuhlane
- amava okuhlanza okanye uhudo oludlulayo
Imithombo:
Erlotinib, MedlinePlus, iThala leNcwadi likaMatriki ka-US, elihlaziywe 07/01/2009.
Wacker B, Nagrani T, Weinberg J, et al. Ulungelelaniso phakathi kokuphuhliswa kokugqithisa nokusebenza kwezigulane eziphathwe nge-epidermal ukukhula kwe-factor receptor tyrosine kinase inhibitor erlotinib kwizifundo ezibini zesigaba III esikhulu. Can Cancer Res. 2007; 13 (13): 3913-3921.